CureVac AG, which is developing vaccines based on messenger RNA technology, has raised $29.5 million from two new German investors to advance its portfolio. This follows a private share placement in 2015 that raised $110 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
